The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder

Movement Disorders

Volumn 33, Issue 1, 2018, Pages 88-98

  Heintz Buschart, Anna ^a   Pandey, Urvashi ^a   Wicke, Tamara ^b,c   Sixel Döring, Friederike ^b,c   Janzen, Annette ^c   Sittig Wiegand, Elisabeth ^c   Trenkwalder, Claudia ^b,d   Oertel, Wolfgang H ^c   Mollenhauer, Brit ^b,d   Wilmes, Paul ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b Paracelsus Elena Klinik   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

16S rRNA gene amplicon sequencing; genome reconstructions; nonmotor phenotype; PD; RBD

Indexed keywords

ARCHAEAL RNA; BACTERIAL RNA; RNA 16S; RNA 18S;

AGED; AKKERMANSIA; ANAEROTRUNCUS; ARCHAEON; ARTICLE; BACTERIAL GENOME; BACTEROIDES; CLOSTRIDIUM; COHORT ANALYSIS; COMMUNITY STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORYNEBACTERIUM; FECES ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMAN; IDIOPATHIC DISEASE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; METAGENOMICS; MICROBIAL DIVERSITY; MICROFLORA; NASAL LAVAGE FLUID; NONHUMAN; NOSE; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; RNA SEQUENCE; CASE CONTROL STUDY; GENETICS; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; NOSE; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER; RNA, RIBOSOMAL, 16S; RNA, RIBOSOMAL, 18S;

EID: 85028341294     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27105     Document Type: Article

References (86)

1. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011;6:e28032.
2. Beach TG, White CL III, Hladik CL, et al. Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2008;117:169-174.
3. Arizona Parkinson's Disease Consortium, Beach TG, Adler CH, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
4. Mu L, Sobotka S, Chen J, et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 2013;72:119-129.
5. Doppler K, Jentschke HM, Schulmeyer L, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. Acta Neuropathol 2017;133:535-545.
6. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
7. Svensson E, Horváth-Puhó E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015;78:522-529.
8. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
9. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013;50:42-48.
10. Dobbs SM, Dobbs RJ, Weller C, et al. Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol 2015;22:22-32.
11. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599-614.
12. Hoglinger GU, Alvarez-Fischer D, Arias-Carrion O, et al. A new dopaminergic nigro-olfactory projection. Acta Neuropathol 2015;130:333-348.
13. Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898.
14. Chen SG, Stribinskis V, Rane MJ, et al. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Sci Rep 2016;6:34477.
15. Scheperjans F, Aho V, Pereira PAB, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015;30:350-358.
16. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;30:1351-1360.
17. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016;32:66-72.
18. Hasegawa S, Goto S, Tsuji H, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLoS One 2015;10:e0142164.
19. Hill-Burns EM, Debelius JW, Morton JT, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 2017;32:739-749.
20. Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. Genome Med 2017;9:39.
21. Hopfner F, Künstner A, Müller SH, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res 2017;1667:41-45.
22. Scheperjans F. Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle. Curr Opin Neurol 2016;29:773-780.
23. Pereira PA, Aho VT, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Oral and nasal microbiota in Parkinson's disease. Parkinsonism Relat Disord 2017;38:61-67.
24. Schrag A, Horsfall L, Walters K, Noyce A. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14:57-64.
25. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013;14:744-748.
26. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
27. Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 2016;87:168-177.
28. Mollenhauer B, Trautmann E, Sixel-Doring F, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013;81:1226-1234.
29. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14:795-806.
30. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
31. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306-1312.
32. Gauggel S, Birkner B. [Validity and reliability of a German version of the Geriatric Depression Scale (GDS)]. [Article in German]. Z Klin Psychol Psych 1999;28:18-27.
33. Schmidtke A, Fleckenstein P, Moises W, Beckmann H. [Studies of the reliability and validity of the German version of the Montgomery-Asberg Depression Rating Scale (MADRS)]. [Article in German]. Schweiz Arch Neurol Psychiatr (1985) 1988;139:51-65.
34. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
35. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
36. Bloch KE, Schoch OD, Zhang JN, Russi EW. German version of the Epworth Sleepiness Scale. Respiration 1999;66:440-447.
37. Schoenebeck B, May C, Güldner C, et al. Improved preparation of nasal lavage fluid (NLF) as a noninvasive sample for proteomic biomarker discovery. Biochim Biophys Acta 2015;1854:741-745.
38. Heintz-Buschart A, May P, Laczny CC, et al. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes. Nat Microbiol 2016;2:16180.
39. Roume H, Muller EE, Cordes T, Renaut J, Hiller K, Wilmes P. A biomolecular isolation framework for eco-systems biology. ISME J 2013;7:110-121.
40. Mathay C, Hamot G, Henry E, et al. Method optimization for fecal sample collection and fecal DNA extraction. Biopreserv Biobank 2015;13:79-93.
41. Wampach L, Heintz-Buschart A, Hogan A, et al. Colonization and succession within the human gut microbiome by archaea, bacteria and microeukaryotes during the first year of life. Front Microbiol 2017;8:738.
42. Hildebrand F, Tadeo R, Voigt AY, Bork P, Raes J. LotuS: an efficient and user-friendly OTU processing pipeline. Microbiome 2014;2:30.
43. Hugerth LW, Muller EE, Hu YO, et al. Systematic design of 18S rRNA gene primers for determining eukaryotic diversity in microbial consortia. PLoS One 2014;9:e95567.
44. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2014.
45. Narayanasamy S, Jarosz Y, Muller EE, et al. IMP: a pipeline for reproducible metagenomic and metatranscriptomic analyses. Genome Biol 2016;17:260.
46. Laczny CC, Muller EE, Heintz-Buschart A, et al. Identification, recovery, and refinement of hitherto undescribed population-level genomes from the human gastrointestinal tract. Front Microbiol 2016;7:533.
47. Aziz RK, Bartels D, Best AA, et al. The RAST Server: rapid annotations using subsystems technology. BMC Genomics 2008;9:75.
48. Oksanen J, Blanchet FG, Kindt R, et al. The vegan package. Community ecology package 2007;10:631-637.
49. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8:e61217.
50. Paradis E, Claude J, Strimmer K. APE: Analyses of phylogenetics and evolution in R language. Bioinformatics 2004;20:289-290.
51. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:1-6.
52. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One 2010;5:e9490.
53. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016;352:565-569.
54. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:31.
55. Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis 2015;26:27663.
56. Jun SR, Robeson MS, Hauser LJ, Schadt CW, Gorin AA. PanFP: pangenome-based functional profiles for microbial communities. BMC Res Notes 2015;8:479.
57. Di Rienzi SC, Sharon I, Wrighton KC, et al. The human gut and groundwater harbor non-photosynthetic bacteria belonging to a new candidate phylum sibling to Cyanobacteria. eLife 2013;2:e01102.
58. Rantala-Ylinen A, Kana S, Wang H, et al. Anatoxin-a Synthetase Gene Cluster of the Cyanobacterium Anabaena sp. Strain 37 and Molecular Methods To Detect Potential Producers. Appl Environ Microbiol 2011;77:7271-7278.
59. Méjean A, Paci G, Gautier V, Ploux O. Biosynthesis of anatoxin-a and analogues (anatoxins) in cyanobacteria. Toxicon 2014;91:15-22.
60. Kellmann R, Mihali TK, Jeon YJ, Pickford R, Pomati F, Neilan BA. Biosynthetic Intermediate Analysis and Functional Homology Reveal a Saxitoxin Gene Cluster in Cyanobacteria. Appl Environ Microbiol 2008;74:4044-4053.
61. Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLoS One 2015;10:e0134802.
62. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015;6:e00037.
63. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-214.
64. Biswas K, Hoggard M, Jain R, Taylor MW, Douglas RG. The nasal microbiota in health and disease: variation within and between subjects. Front Microbiol 2015;9:134.
65. Bassis CM, Tang AL, Young VB, Pynnonen MA. The nasal cavity microbiota of healthy adults. Microbiome 2014;2:27.
66. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262-266.
67. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 2015;65:57-62.
68. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. Sci Rep 2016;6:39399.
69. Kong F, Hua Y, Zeng B, Ning R, Li Y, Zhao J. Gut microbiota signatures of longevity. Curr Biol 2016;26:R832-R833.
70. Reunanen J, Kainulainen V, Huuskonen L, et al. Akkermansia muciniphila. adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl Environ Microbiol 2015;81:3655-3662.
71. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107-113.
72. Ottman N, Reunanen J, Meijerink M, et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One 2017;12:e0173004.
73. Desai MS, Seekatz AM, Koropatkin NM, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 2016;167:1339-1353.e21.
74. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016;167:1469-1480.e12.
75. Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: implications for non-motor symptoms. Parkinsonism Relat Disord 2016;27:1-8.
76. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015;48:186-194.
77. Aizawa E, Tsuji H, Asahara T, et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord 2016;202:254-257.
78. Kelly JR, Borre Y, O'Brien C, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res 2016;82:109-118.
79. Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host. Mol Psychiatry 2016;21:786-796.
80. Sunagawa S, Mende DR, Zeller G, et al. Metagenomic species profiling using universal phylogenetic marker genes. Nat Methods 2013;10:1196-1199.
81. Cox PA, Banack SA, Murch SJ, et al. Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. Proc Natl Acad Sci U S A 2005;102:5074-5078.
82. Dunlop RA, Cox PA, Banack SA, Rodgers KJ. The non-protein amino acid BMAA is misincorporated into human proteins in place of l-serine causing protein misfolding and aggregation. PLoS One 2013;8:e75376.
83. Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 2004;110:267-269.
84. Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand 2009;120:216-225.
85. Downing S, Downing TG. The metabolism of the non-proteinogenic amino acid β-N-methylamino-L-alanine (BMAA) in the cyanobacterium Synechocystis PCC6803. Toxicon 2016;115:41-48.
86. Durso LM, Smith D, Hutkins RW. Measurements of fitness and competition in commensal Escherichia coli and E. coli O157:H7 strains. Appl Environ Microbiol 2004;70:6466-6472.